In:
Biomarkers in Medicine, Future Medicine Ltd, Vol. 17, No. 10 ( 2023-05), p. 475-485
Abstract:
Background: This study aimed to determine whether novel and conventional cardiorenal biomarkers in patients before transcatheter aortic valve implantation may be associated with cardiorenal syndrome (CRS) type 1. Methods: Serum NT-proBNP and urine biomarkers (hepcidin-25, NGAL, IL-6) were measured before and 24 h after transcatheter aortic valve implantation. Results: 16/95 patients had CRS type 1. Those patients had longer length of stay in hospital (12.5 [9.0–16.0] vs 9.0 [8–12] days; p = 0.025) and were more frequently readmitted to hospital within 6 months after discharge (46.7 vs 15.6%; odds ratio: 4.7; 95% CI: 1.5–15.5; p = 0.007). The NT-proBNP/urine hepcidin-25 ratio (odds ratio: 2.89; 95% CI: 1.30–6.41; p = 0.009) was an independent modifier of CRS type 1. Conclusion: The NT-proBNP/urine hepcidin-25 ratio appears to be a modifier of risk of CRS type 1.
Type of Medium:
Online Resource
ISSN:
1752-0363
,
1752-0371
DOI:
10.2217/bmm-2023-0034
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023
Permalink